ADVFN Logo ADVFN

Não encontramos resultados para:
Verifique se escreveu corretamente ou tente ampliar sua busca.

Tendências Agora

Rankings

Parece que você não está logado.
Clique no botão abaixo para fazer login e ver seu histórico recente.

Cadastre-se

Já é membro? Faça login

Moneta Markets

Abrir Conta

Moneta Markets
Dados
Notícias
Ferramentas
Mercados
Comunidade

Recursos principais

Follow Feed

Conecte-se com traders e investidores em nossa comunidade Follow Feed.

Fluxo de Opções

Explore dados abrangentes de opções e utilize filtros avançados com Fluxo de Opções.

Monitor

Organize e monitore sua lista de ações e ativos com o Monitor.
AI Entrar Premium IconPremium Help Menu
Índice Bovespa
122.522,44
0,03%
S&P 500
6.106,54
-0,20%
US Dollar vs BRL
5,8957
-0,51%
Bitcoin
106.995,14
2,91%
Brent Oil
77,525
0,25%
As Melhores Corretoras Online
Registration Strip Icon for default Cadastre-se gratuitamente para obter cotações em tempo real, gráficos interativos, fluxo de opções ao vivo e muito mais.
Cadastre-se
  1. Início
  2. Investir
  3. Ações
  4. EUA
  5. NASDAQ
  6. Immunic Inc (IMUX)

  7. Immunic Inc (IMUX) Notícias

IMUX

Immunic (IMUX)

Immunic Inc
De:
Ordenação:
 Apresentando as notícias mais relevantes sobre:NASDAQ:IMUX
DataHoraFonteTítuloCódigoCompanhia
13/01/202510:32Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:IMUXImmunic Inc
07/01/202508:30PR Newswire (US)Immunic Highlights 2024 Accomplishments and Upcoming MilestonesNASDAQ:IMUXImmunic Inc
09/12/202410:30Edgar (US Regulatory)Form 4/A - Statement of changes in beneficial ownership of securities: [Amend]NASDAQ:IMUXImmunic Inc
06/12/202419:32Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
26/11/202408:30PR Newswire (US)Immunic, Inc. to Participate in Investor Conference in DecemberNASDAQ:IMUXImmunic Inc
14/11/202419:33Edgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:IMUXImmunic Inc
13/11/202408:30PR Newswire (US)Immunic Announces Publication of Data From Phase 1/1b Clinical Trial of IMU-856 in the Peer Reviewed Journal, The Lancet Gastroenterology & HepatologyNASDAQ:IMUXImmunic Inc
12/11/202411:31Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:IMUXImmunic Inc
07/11/202409:04Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:IMUXImmunic Inc
07/11/202408:30PR Newswire (US)Immunic, Inc. Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:IMUXImmunic Inc
31/10/202407:30PR Newswire (US)Immunic, Inc. to Announce Financial Results for the Third Quarter Ended September 30, 2024, and Provide Corporate UpdateNASDAQ:IMUXImmunic Inc
29/10/202407:30PR Newswire (US)Immunic to Participate in Industry, Scientific and Investor Conferences in NovemberNASDAQ:IMUXImmunic Inc
22/10/202407:30PR Newswire (US)Immunic Announces Positive Outcome of Interim Analysis of Phase 3 ENSURE Program of Vidofludimus Calcium in Relapsing Multiple SclerosisNASDAQ:IMUXImmunic Inc
18/09/202407:30PR Newswire (US)Immunic Presents Key Vidofludimus Calcium Data at the 40th Congress of ECTRIMS, Highlighting Its Therapeutic Potential in Multiple SclerosisNASDAQ:IMUXImmunic Inc
04/09/202407:30PR Newswire (US)Immunic Announces First Patient Enrolled in Investigator-Sponsored Phase 2 Clinical Trial of Vidofludimus Calcium in Patients with Post COVID SyndromeNASDAQ:IMUXImmunic Inc
28/08/202407:30PR Newswire (US)Immunic to Host Multiple Sclerosis R&D Day and Participate in Scientific and Investor Conferences in SeptemberNASDAQ:IMUXImmunic Inc
08/08/202407:30PR Newswire (US)Immunic, Inc. Reports Second Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:IMUXImmunic Inc
01/08/202407:30PR Newswire (US)Immunic, Inc. to Announce Financial Results for the Second Quarter Ended June 30, 2024, and Provide Corporate UpdateNASDAQ:IMUXImmunic Inc
24/07/202417:10Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:IMUXImmunic Inc
24/07/202407:30PR Newswire (US)Immunic, Inc. Strengthens Its Board of Directors with the Appointment of Experienced Pharmaceutical Executive Simona SkerjanecNASDAQ:IMUXImmunic Inc
09/07/202407:30PR Newswire (US)Immunic Appoints Jason Tardio as Chief Operating Officer and PresidentNASDAQ:IMUXImmunic Inc
10/06/202417:05Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:IMUXImmunic Inc
03/06/202401:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:IMUXImmunic Inc
28/05/202407:30PR Newswire (US)Immunic to Participate in Industry and Scientific Conferences in JuneNASDAQ:IMUXImmunic Inc
24/05/202417:06Edgar (US Regulatory)Form S-3/A - Registration statement under Securities Act of 1933: [Amend]NASDAQ:IMUXImmunic Inc
08/05/202407:30PR Newswire (US)Immunic, Inc. Reports First Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:IMUXImmunic Inc
06/05/202407:30PR Newswire (US)Immunic to Participate in Investor and Scientific Conferences in MayNASDAQ:IMUXImmunic Inc
01/05/202407:30PR Newswire (US)Immunic, Inc. to Announce Financial Results for the First Quarter Ended March 31, 2024, and Provide Corporate UpdateNASDAQ:IMUXImmunic Inc
30/04/202407:30PR Newswire (US)Immunic Announces Publication of Extended Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis in the Peer Reviewed Journal, Neurology® Neuroimmunology & NeuroinflammationNASDAQ:IMUXImmunic Inc
04/04/202407:30PR Newswire (US)Immunic to Host MS R&D Day and Participate in Investor Conferences in AprilNASDAQ:IMUXImmunic Inc
 Apresentando as notícias mais relevantes sobre:NASDAQ:IMUX

Seu Histórico Recente

BIT
P1LRO3
BNP Paribas Issuance
BIT
UC7LVF
Unicredit Bank
BIT
Q00100
Leonteq Securities
NASDAQ
FBSQX
Agf Global Strategic Inc...
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

Brasil
Empresa
Negócios
Popular
Obter o aplicativo
App Store
Google Play

Suporte: (11) 4950 5808 | suporte@advfn.com.br

Ao acessar os serviços da ADVFN você estará de acordo com os Termos e Condições

© 2025 ADVFN PLC - Todos os direitos reservados